EMEA-002515-PIP01-18
Table of contents
Key facts
Active substance |
Human immunoglobulin G2 isotype antibody to IL-33R
|
Therapeutic area |
Pneumology-allergology
|
Decision number |
P/0055/2020
|
PIP number |
EMEA-002515-PIP01-18
|
Pharmaceutical form(s) |
Powder for solution for injection
|
Condition(s) / indication(s) |
Treatment of asthma
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
GlaxoSmithKline Trading Services Limited
Tel. +1 4388998201 |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|